TY - JOUR
T1 - Anti-CD133 Monoclonal Antibody CMab-43 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer
AU - Kato, Yukinari
AU - Ohishi, Tomokazu
AU - Yamada, Shinji
AU - Itai, Shunsuke
AU - Furusawa, Yoshikazu
AU - Sano, Masato
AU - Nakamura, Takuro
AU - Kawada, Manabu
AU - Kaneko, Mika K.
N1 - Funding Information:
We thank Akiko Harakawa, Shun-ichi Ohba, Miyuki Yanaka, Kayo Hisamatsu, Saori Handa, and Yoshimi Naka-mura for their excellent technical assistance. This research was supported in part by AMED under grant nos. JP18am0101078 (Y.K.), JP18am0301010 (Y.K.), and JP18ae0101028 (Y.K.), and by JSPS KAKENHI grant no. 17K07299 (M.K.K.) and grant no. 16K10748 (Y.K.).
Publisher Copyright:
© 2019, Mary Ann Liebert, Inc.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Cancer stem cells contribute to tumorigenesis, metastasis, recurrence, and chemoresistance. CD133/prominin-1 - a pentaspan membrane glycoprotein - has been used as a stem cell biomarker for the isolation of stem-like cells from a variety of normal and pathological tissues. In our previous studies, we developed several anti-CD133 monoclonal antibodies using Cell-Based Immunization and Screening (CBIS) methods, followed by characterization of their efficacy by flow cytometry, western blotting, and immunohistochemical analyses. One of the 100 clones, CMab-43 (IgG2a, kappa), demonstrated a sensitive and specific reaction against colon cancer cells. This study aimed to investigate the antitumor activity of CMab-43. Caco-2 cells (human colon cancer cell line) were subcutaneously implanted into the flanks of nude mice. CMab-43 and control mouse IgG were injected three times into the peritoneal cavity of mice. Tumor formation was observed in the control and CMab-43-treated mice of Caco-2 xenograft models. CMab-43 significantly reduced tumor development of Caco-2 xenograft in comparison with the control mouse IgG on days 12, 14, and 17. Our results cumulatively suggest that CMab-43 is useful for antibody therapy against CD133-expressing colon cancers.
AB - Cancer stem cells contribute to tumorigenesis, metastasis, recurrence, and chemoresistance. CD133/prominin-1 - a pentaspan membrane glycoprotein - has been used as a stem cell biomarker for the isolation of stem-like cells from a variety of normal and pathological tissues. In our previous studies, we developed several anti-CD133 monoclonal antibodies using Cell-Based Immunization and Screening (CBIS) methods, followed by characterization of their efficacy by flow cytometry, western blotting, and immunohistochemical analyses. One of the 100 clones, CMab-43 (IgG2a, kappa), demonstrated a sensitive and specific reaction against colon cancer cells. This study aimed to investigate the antitumor activity of CMab-43. Caco-2 cells (human colon cancer cell line) were subcutaneously implanted into the flanks of nude mice. CMab-43 and control mouse IgG were injected three times into the peritoneal cavity of mice. Tumor formation was observed in the control and CMab-43-treated mice of Caco-2 xenograft models. CMab-43 significantly reduced tumor development of Caco-2 xenograft in comparison with the control mouse IgG on days 12, 14, and 17. Our results cumulatively suggest that CMab-43 is useful for antibody therapy against CD133-expressing colon cancers.
KW - CD133
KW - Caco-2
KW - colon cancers
KW - monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=85065109463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065109463&partnerID=8YFLogxK
U2 - 10.1089/mab.2019.0002
DO - 10.1089/mab.2019.0002
M3 - Article
C2 - 30969150
AN - SCOPUS:85065109463
SN - 2167-9436
VL - 38
SP - 75
EP - 78
JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
IS - 2
ER -
